

# Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review

## Abstract

With obesity growing by leaps and bounds, being responsible for millions of deaths either directly or indirectly through its complications like type 2 diabetes mellitus (T2M), Metabolic syndrome, various cancers there is need for medical answers to effectively combat it. With the pharmaceutical drugs getting developed and shunted out of market with undesirable side effects directions are being shifted towards more physiological methods using some plant extracts like thylakoids, various anthocyanins etc to combat Insulin Syndrome (IRS), T2DM similarly attention is being moved to modify gut microbiota with the use of probiotics and synbiotics. Till date most beneficial strains have been developed from *Lactobacillus* or *Bifidobacteria*. Although a promising strategy both in animal and human models still human trials have remained few with inconsistent results. Hence need for long term studies with more bacterial strains are desired to ensure Probiotics become an established method of treating obesity. Thus we carried out this review to understand what is the status of use of these Probiotics and synbiotics in human trials in patients having obesity, T2DM, Hypertension, IRS, nonalcoholic fatty liver disease (NAFLD) and steatohepatitis.

**Keywords:** obesity, T2DM, NAFLD, Cancer, Probiotics, synbiotics, bariatric surgery, medical pharmacotherapy of obesity

Volume 9 Issue 1 - 2019

Kulvinder Kochar Kaur,<sup>1</sup> Gautam Allahbadia,<sup>2</sup> Mandeep Singh<sup>3</sup>

<sup>1</sup>Kulvinder Kaur Centre For Human Reproduction, India

<sup>2</sup>Scientific Director Ex-Rotunda-A Centre for Human reproduction Consultant Neurologist, India

<sup>3</sup>Swami Satyan and Hospital, Near Nawi Kachehri, Baradri, Ladowali road, India

**Correspondence:** Kulvinder Kaur, Scientific Director, Centre For Human Reproduction, 721, G.T.B. Nagar Jalandhar-144001, Punjab, India, Tel -91-181-9501358180, 91-181-4613422, Fax-91-181-4613422, Email kulvinder.dr@gmail.com

**Received:** February 13, 2018 | **Published:** February 28, 2018

## Introduction

Obesity continues to be a big public health problem, with its prevalence increasing continuously. As per the WHO it has been estimate that In last 40 years, obesity prevalence almost tripled and in 2016, over 650million people around the world, which included various million infants and children became obese.<sup>1</sup> Increased body weight is associated with development of several severe chronic conditions like type 2 diabetes mellitus, (T2DM), cardiovascular disease (CVD), musculoskeletal disorders and different cancers.<sup>2</sup> Every year because of overweight/obesity, there are 28million deaths worldwide.<sup>2</sup> Further obesity leads to a big medical, social and economic burden.<sup>3</sup> We have been trying to find simple answers for treating obesity, medically, the problem remains that gradually most of the previous approved medications for obesity have got removed from the market, in view of different side effects, along with their inability to maintain long term weight loss.<sup>4-8</sup> Although interventions like bariatric surgery are the most effective till date for reducing increased weight in people with morbid obesity, it is a very invasive procedure, having risks of unforeseen complications along with needing marked effort in adopting a new lifestyle [reviewed in ref.<sup>9</sup> Thus need for looking simpler approaches is there. Symbiosis has been described in nonalcoholic steatohepatitis (NASH),<sup>10,11</sup> T2DM, metabolic syndrome,<sup>12-15</sup> and obesity.<sup>16,17</sup> As far as overweight/obesity, is concerned various studies have demonstrated that the gut micro bio decomposition may be significantly different from lean individuals, the faecal bacteria may exert a key role in modulating energy metabolism with modifications of gut microbiotacomposition might be associated with decreases In body mass index (BMI)<sup>16,17</sup> Reviewed in ref. <sup>5,18,19</sup> In view of this manipulation of gut microbiota composition using probiotics has been considered a possible way for preventing and treating obesity. The word probiotic comes from the Greek word, which means "for life". Despite lot of change in definitions, currently the definition recognized by Food and Agricultural Organization of the

United Nations (FAO) and world health organization (WHO) working group experts is that probiotics are live strains of strictly selected microorganisms, which once administered in adequate amounts, give a health benefit to the host.<sup>20</sup> This definition was accepted by the International Scientific Association of Probiotics and Probiotics (ISAPP) in 2013.<sup>21</sup> Though dead bacteria and their components can also show probiotic properties. Most commonly used bacterial strains are Bifidobacteria and Lactobacillus that exhibit probiotic properties and get included in many functional foods and dietary supplements.<sup>22</sup> Main mechanisms of actions of probiotics are improvement of the gut barrier function, increasing competitive adherence to the mucosa and epithelium, modification of gut microbiota, along with regulation of the gut associated lymphoid immune system. Thus probiotics communicate with the host utilizing intestinal cell pattern recognition receptors, like toll like receptors and nucleotide binding oligomerization domain containing protein like receptors that modulate important vital signaling pathways like nuclear factor kappa B (NFκB) and mitogen activated protein kinase to increase or suppress either activation or effect downstream pathways.<sup>21,23-26</sup> A Probiotics is a nonviable food component which gives a health benefit on the host associated with modulation of microbiota, which might be a fiber, but all fibers are not necessarily a Probiotics. Usage of probiotic and Probiotics together is often known as synbiotic, if the net health benefit is synergistic<sup>27</sup> Probiotics and synbiotics are taken in multiple and varied forms, like yogurt and other fermented milks, cheese and various fermented foods besides in the prevention and treatment of different gastrointestinal (GI) tract dysfunctions and other diseases like allergy.<sup>28</sup> However the actual effects of how probiotic changes intestinal ecology is still debatable, in view of various confounding elements, like dissimilarities in microbial strains, concentrations of viable cells and product formulations.<sup>29-31</sup> Yao and Kim showed that probiotics and Probiotics affect type2 diabetes mellitus (T2DM), and cardio vascular disease (CVD) by changing gut microbiota, regulating insulin signaling, along with lowering cholesterol.<sup>32</sup> Thus the aim of

this review was to study if probiotics and synbiotics are effective in the prevention along with treatment of obesity, IRS, T2DM, non alcoholic fatty liver disease (NAFLD) in human studies.

## Methods

We carried out a Pubmed Search for articles related to obesity, Role of Probiotics in Obesity, type2 diabetes mellitus, nonalcoholic liver fatty disease/steatohepatitis, treatment with probiotics, Synbiotics from 1990's to 2018.

## Results

We found a total of 863 articles relevant to this field of which we selected 76 articles for this review. Further references were obtained from cross references obtained from the original articles. No meta-analysis was done. On testing *Lactobacillus salivarius* Ls 33 in obese adolescents, for studying what effects it causes on fecal microbes, along with anthropometric data, inflammation related biomarkers, carbohydrate and lipid metabolism, the following results were found. Ratios of Bacteroides, Prevotellae and Porphyromonas group of bacteria to Firmicutes-group, that included Clostridium cluster XIV, *Blautia coccooides*, Eubacterium rectal group and Roseburia intestinalis were markedly increased following *Lactobacillus salivarius* Ls.<sup>33</sup> But the overall cell numbers of fecal bacteria which included the above groups along with Clostridium cluster I and cluster IV, *Faecalibacterium prausnitzii*, Enterobacteriaceae, *Enterococcus*, *Lactobacillus* group and *Bifidobacterium* spp, were not changed much with this treatment. Also short chain amino acids (SCFA's) remained unchanged.<sup>33</sup> Further an intervention study was done by Gobel et al.,<sup>34</sup> using *Lactobacillus salivarius* Ls 33 on effects of inflammation biomarkers along with different aspects of metabolic syndrome in adolescents having obesity. No changes were found in these parameters. Two studies used a cohort of Japanese adults having large visceral fat areas (VFA) to examine the effect of *L. gasseri* SBT2055. They assigned participants into 3 groups getting increasing colony forming units (CFUs) of *L. gasseri* SBT2055 for 12 weeks. A decrease in body mass index (BMI), waist, abdominal VFA and hip circumferences were noted [35,36]. Similarly Sharafeditinov et al studied use of a hypocalorie diet that was supplemented with a probiotic enriched cheese that contained *Lactobacillus plantarius* and found this decreased the BMI, the putrescine content and the intestinal lactobacillus content in Russian adults having obesity along with hypertension. A lower diastolic blood pressure along with tendency towards lower systolic BP was seen in this group.<sup>37</sup> Giving *Lactobacillus. Acidophilus* La 5, *B. lactis* Bb 12 and *L. Casei* was examined in people having high BMI, after randomly dividing them into 3 groups based on a specific intervening diet; first group received regular yogurt with low calorie diet (RLCD). The second one got a Probiotics yogurt with low calorie diet (PLCD), While 3<sup>rd</sup> received a probiotic yogurt without low calorie diet (PWLCD) for roughly 2 months. A decrease in BMI, fat percentage and leptin was seen and was more so in groups that received weight loss diet including probiotic yogurt. But a decrease in serum levels of CRP was observed more in the PWLCD group s compared to PLCD and RLCD groups following 2mths of treatment. FOXP3, T-bet, GATA-3, TNF- $\alpha$ , IFN $\gamma$ , TGF $\beta$  and ROR $\gamma$ I genes expression was examined in peripheral blood mononuclear cells (PBMC's) both before and after the intervention. ROR $\gamma$ I expression was decreased in all 3 groups, while FOXP3 increased. GATA-3, TNF- $\alpha$ , TGF $\beta$  expression did not change. Though funnily T-bet gene expression got down regulated in all groups. Thus a suggestion that weight loss diet and probiotic yogurt had effects on gene expression in PBMC in overweight and obese individuals was given by the authors.<sup>38-40</sup> In another study an 8 weeks randomized,

double blind, placebo and compliance controlled parallel study was done by Agerholm-Larsen et al in overweight and obese individuals to examine the effects of one strain of *E. faecium* and 2 strains of *S. thermophilus*.<sup>41</sup> Randomly patients were divided in five groups; 1) a yogurt fermented with 2 strains of *S. thermophilus* and 2 strains of *L. acidophilus*; 2) a placebo yogurt fermented with delta -acid lactone; 3) a yogurt fermented with 2 strains of *S. thermophilus* and one strain of *L. rhamnosus*; 4) a yogurt fermented with one strain of *E. faecium* and 2 strains of *S. thermophilus* and 5) 2 placebo pills daily.<sup>39</sup> Following adjustment for small changes in body weight, low density lipoprotein cholesterol (LDL-C) reduced and a significant increase in fibrinogen occurred after 8 wks in the 4<sup>th</sup> group i.e the one receiving a yogurt fermented with one strain of *E. faecium* and 2 strains of *S. thermophilus* as compared to the one getting chemically fermented yogurt and the placebo pill group. Further systolic BP got significantly decreased following 8 weeks in group 4 the one receiving a yogurt fermented with one strain of *E. faecium* and 2 strains of *S. thermophilus* as well as in group 1 in contrast to group 3.<sup>41</sup> *Bifidobacterium*, lactobacilli and *S. thermophilus* was given in the form of capsules to overweight subjects by Rajkumar et al. They found that this probiotic mixture, significantly improved the lipid profiles, decreasing total cholesterol (TC), triacylglycerol (TAG) and LDL-C levels while simultaneously increasing high density lipoprotein cholesterol (HDL-C) levels. Further this probiotic mixture, improved the insulin sensitivity along with decreasing C - reactive protein (CRP).<sup>42</sup> While in a single blind parallel group intervention of 6 week duration, 58 obese, premenopausal women were randomized into a daily intake of *L. paracasei* F19, flax mucilage or placebo. *L. paracasei* F19 did not alter any of the metabolic markers (like homeostatic model of insulin resistance (HOMA-IR), Matsuda index, CRP and lipid profile compared with placebo.<sup>43</sup> similarly intake of *L. acidophilus*. La 5 and *B. animalis sub sp lactis* Bb 12 did not affect HOMA-IR, BP, heart rate or serum lipid concentrations in over weight adults.<sup>44,45</sup>

## Role of synbiotics

Effect of *L. Rhamnosus* CGMCCI 3274 with oligofructose and insulin supplementation was studied on weight loss and maintenance in obese men and women.<sup>46</sup> Mean weight loss in women in the *L. Rhamnosus* group was markedly > than in women in the placebo group after the 1<sup>st</sup> 12 weeks, while it was similar in men in both groups. The *L. Rhamnosus* induced weight loss in women besides causing significant decrease in fat mass and circulating leptin concentrations also caused a relative increase of the bacteria of the *L. achnospinaceae* family in the faeces, a family that belongs to the Formicetes phylum, a taxonomic group that is known to be positively associated with obesity.<sup>46</sup> The examination of synbiotic supplementation on cardio metabolic risk factors, anthropometric profile, serum lipid levels along with oxidative stress levels in obese children was done in 2 studies. Synbiotic intake caused a significant decrease in the BMI-z- Score and waist circumference (WC), along with some cardio metabolic risk factors like TC, LDL-C and TAG.<sup>38,39</sup> besides changes in anthropometric profile (percentage reduction as compared to baseline) were significantly > in children getting synbiotics. Total oxidative stress levels also got significantly reduced following synbiotic addition.<sup>47,48</sup> Thus selected probiotics once added seem to benefit, BMI, WC, VFA, hip circumference in overweight/obese people. Further some probiotic strains alter the gene expression of particular transcription factors like down regulation of ROR $\gamma$ I and up regulation of FOX-P3 in PBMCs, which was accompanied by beneficial changes in the immune system in overweight/obese subjects. Y et administration of *L. paracasei* F19 and *L. acidophilus* La5 and *B. animalis sub spp lactis* Bb12 did not change the levels of inflammatory biomarkers. Some synbiotics decrease BMI in women; reduce fat mass along with serum

leptin levels, increasing the *Lachnospiraceae* family in the faeces. Further synbiotic treatment help in reducing BMI-z-score and WC in children along with TC, LDL-C and TAG serum levels.

## Role in insulin resistance syndrome (IRS)

### Role of probiotics

Effects of *Lactobacillus casei* Shirota was examined in patients having IRS, to study gut permeability, presence of endotoxin and neutrophils function, insulin sensitivity index, quantitative insulin sensitivity check index, insulin sensitivity by oral glucose tolerance test, HOMA-IR and  $\beta$  cell function. There was an increase in gut permeability, but no change in endotoxin and neutrophil function.<sup>49</sup> In postmenopausal women IRS is a known risk factor for cardiovascular morbidity, like coronary heart disease and stroke. Boretta et al studied the efficacy of *L. plantarium*/placebo in postmenopausal women over a time span of 90 days. They found the TC, interleukin-6 (IL-6), gamma glutaryl transpeptidase ( $\gamma$ -GTP), levels markedly reduced in both groups at the end of the study, while LDL-C was significantly low in the placebo group. Both glucose and homocysteine levels got significantly lowered in the *L. plantarium* group as compared to placebo.<sup>50</sup> Renorio-Jimenez et al conducted a double blind, randomized, crossover, placebo controlled and a single centre trial where 60 participants (18-65 years), diagnosed with IRS was to be randomized in a 1:1 ratio to receive either a single daily dose of placebo or colony forming units of *L. reuteri* V 3401. This study has 2 intervention periods of 12 weeks separated by a washout period of 6 weeks and preceded by another washout period of 2 weeks. The primary outcomes will be changes in lipopolysaccharide (LPS) levels at 12 weeks. Secondary outcomes will include anthropometric parameters, lipid profile, glucose metabolism, microbiota composition, hepatic steatosis and inflammatory and CVS biomarkers. Blood and stool samples would be collected at baseline, at midpoint (only stool samples) and immediately following each intervention period. Luminex technology will measure interleukins. Thus for the 1<sup>st</sup> time *L. reuteri* V 3401 will be evaluated in patients with IRS. Hence this study will provide valuable scientific information about the effects of this strain in IRS and metabolic syndrome patients.<sup>51</sup>

### Role of synbiotics

Either synbiotic capsules having 7 strains along with fructooligosaccharide or placebo capsules for examining IR and lipid profile in patients having IRS were tried. Significant improvement in fasting blood sugar and IR was seen in synbiotic group.<sup>52</sup> Thus some probiotic strains were of benefit by reducing the cell adhesion molecule-1 levels. Further in postmenopausal women, *L. plantarium* reduced TC, interleukin-6 (IL-6), gamma glutaryl transpeptidase ( $\gamma$ -GTP), glucose and homocysteine levels after 90 days. Further the synbiotic mixture improved IR and HDL-C, while reducing the TAG and TC levels in subjects having IRS.

## Role in type 2 diabetes mellitus (T2DM)

### Role of probiotics

The effect of administration of probiotic soymilk containing *L. plantarium* A7 or soymilk alone was studied by Hann et al. This probiotic soymilk or soymilk alone was given daily as a supplement of their diet naturally consumed. Significant reduction in the level of promoter methylation in the proximal and distal MLH1 promoter region as compared to the baseline value. Also a significant increase in superoxide dismutase action was seen in the probiotic soymilk group as compared with the baseline value was observed. But no significant changes were seen in the promoter methylation of MSH2 within

either group. Thus *L. plantarium* A7 inoculated soy milk might have anti oxidative properties, with the risk of mismatched base pairs in DNA among patients with T2DM.<sup>53</sup> Administration of *L. acidophilus* La 5 and *B. animalis* sub spp lactis BB12 was examined in T2DM patients. A marked difference between the groups concerning, mean changes in the HbA1c, TC and LDL-C levels was seen.<sup>54</sup> Additionally an increase in HDL-C levels with a reduction in LDL-C/ HDL-C ratio was found in the treatment group.<sup>55</sup> Earlier studies used the same strains in T2DM patients. A significant reduction in fasting blood glucose, TC, LDL-C and HbA1c were observed, along with increase in erythrocyte superoxide dismutase and glutathione peroxidase activity and total antioxidant status as compared with the control group. Thus a conclusion was drawn that probiotic yogurt seems to be a promising agent for T2DM management, and might act as a functional food having both antidiabetic along with antioxidant activity.<sup>56,57</sup> In a double blind, randomized study, males having T2DM, impaired or normal OGTT were put on a 4 week treatment course, consisting of either *L. acidophilus* NCFM or a placebo to study the effects of oral probiotic supplementation on insulin sensitivity and the inflammatory response.<sup>58</sup> The probiotic strain was found in 75% of the faecal samples, following treatment. Insulin sensitivity got preserved only in volunteers in the *L. acidophilus* NCFM group. Baseline inflammatory markers and the systemic inflammatory response was unaffected by the *L. acidophilus* NCFM supplementation.<sup>58</sup> Further Razanpoosh et al conducted a randomized double blind control trial in 60 patients who were assigned into 2 groups of 30 participants each to take either probiotic supplements or placebo for 6 weeks. The probiotic supplements consisted of 7 viable strains of *Lactobacillus*, *Streptococcus* and *Bifidobacterium*. Nutrient intakes were estimated using a 3 day and 4 hour dietary recall at the beginning and end of study. They found within group comparisons significant decrease in the levels of fasting blood glucose (FBG) ( $P=0.001$ ) and increase in HDL-C ( $P=0.002$ ). No significant changes were seen within and between group comparisons in the levels of insulin, triglycerides, TC, IR, weight, WC and BMI ( $all p>0.05$ ). Thus concluding that a significant decrease in FPG level by multistrain probiotic supplements occurred within group comparisons though they advocated further studies to confirm results.<sup>59</sup>

### Role of synbiotics

Multispecies probiotic supplement consisting of 7 viable and freeze dried strains and fructooligosaccharides was given to T2DM patients to study metabolic profile, CRP and oxidative stress in these patients. HOMA-IR increased significantly in both groups. But this increase was significantly more in the placebo group than in the probiotic group. Mean serum CRP were significantly lower in the patient group. Further probiotic supplementation  $\Rightarrow$  to increased total glutathione levels compared to the placebo.<sup>60</sup> In T2DM patients, clinical trials were done, to study the effects of synbiotic bread containing *L. Sporogenes* and insulin. Significant decrease in serum insulin levels, HOMA-IR, and homeostatic model assessment  $\beta$  cell function, serum lipid profile like TAG, TC/HDL-C occurred following synbiotic bread along with significant increase in HDL-C levels as compared to control bread.<sup>61,62</sup> Another synbiotic shake that contained *L. acidophilus*, *B. bifidum* and fructooligosaccharides was evaluated regarding glycemic control and cholesterol levels in old people having T2DM. In this study TC, TAG, HDL-C along with blood sugar were examined. Only HDL-C increased significantly along with a significant decrease in fasting blood sugar but no change occurred in TC, along with TAG levels in the synbiotic group.<sup>63</sup> Thus some of the probiotic changes seen in T2DM patients, were lowered fasting blood glucose levels, improved insulin sensitivity and an increased antioxidant status. Few synbiotics increased the total glutathione levels, HDL-C and decreased the

fasting glucose levels and CRP. Further improvement in serum lipid profile was seen in T2DM patients consuming synbiotics.

## Role in non alcoholic fatty liver disease


### Role of probiotics

Aller R et al studied the effects of *S. thermophilus* and *L. bulgaris* on different liver function tests along with CV risk factors. A reduction in alanine amino transferase (ALT), aspartate amino transferase (ASP) and  $\gamma$ -GTP indicated improvement of liver function.<sup>64</sup> In obese children having NAFLD, treatment with *L. rhamnosus* strain GG, caused a Significant decrease in the titer of anti-peptidoglycan-poly saccharide antibodies that are suitable as an indicator of SIBO. Further this randomized clinical trial also revealed a restoration of liver function through use of this Probiotics, showing a reduction in ALT.<sup>65</sup> Using a Probiotics yogurt with *L. acidophilus* La 5 and *B. lactis* Bb 12 for 8 weeks in NAFLD in a double blind randomized controlled clinical trial, a reduction in serum levels of ALT, ASP, TC and LDL-C occurred following *L. acidophilus* La 5 and *B. lactis* Bb 12 intake as compared to controls.<sup>66</sup> Alisi et al carried out another randomized study, where they found improvement of fatty liver severity significantly as examined by ultrasound, along with a Significant decrease in the BMI of children having NAFLD after treatment with bifidobacteria, lactobacilli and *S. thermophilus* strain for 4 months, suggesting that these strains might reduce liver fat and thus prevent the progression of NAFLD.<sup>67</sup> Alisi et al also examined glucagon like peptide 1 (GLP1), an incretin secreted by cells of small intestine and proximal colon. They showed that the circulating levels of total and active form of GLP1 were significantly increased in the patients after 4 months of treatment with synbiotics.<sup>67</sup> Though not adequate data is available in humans, it has been seen that treatment with probiotics improves the effectiveness of lifestyle modifications in obese subjects having NAFLD, might improve conventional LFT, and might reduce markers of lipid peroxidation.<sup>64-69</sup> and NASH.<sup>70</sup> Improvement in liver function may be secondary to a decrease in small bowel bacterial overgrowth (SIBO) and/or dysbiosis and thus a minor metabolic endotoxaemia in the host as once normal gut microbiota get reduced there may be a decrease in intestinal permeability.


### Role of Synbiotics

Products derived from bacteria like lipopolysaccharides (LPS), ethanol and SCFA => their arrival from intestine lumen to the liver. Also SCFAs stimulate synthesis and storage of hepatic triacylglycerols. This may => saturation of the detoxification mechanisms => accumulation of intrahepatic triglycerols (IHTG) content, thereby increasing the fatty liver severity. A randomized study using synbiotic made up of 5 probiotics (*L. acidophilus*, *L. plantarius*, *L. delbrueckii* spp. *bulgaricus*, *L. rhamnosus*, *B. bifidum* and insulin) over 6 months in adults having NASH, caused significant reduction in IHTG [70]. That LPS produce pro inflammatory cytokines like tumor necrosis-alpha (TNF- $\alpha$ ), that play a key role in IR and hepatic inflammatory cell recruitment in NAFLD. In a study done in 52 adults over 28 weeks, usage of symbiotic supplementation, that is a mixture of *L. casei*, *L. rhamnosus*, *L. acidophilus*, *S. thermophilus*, *L. bulgaricus*, *B. breve*, *B. longum* and fructo-oligosaccharides, showed that synbiotic supplementation inhibited NF- $\kappa$ B and decreased TNF- $\alpha$  production.<sup>68</sup> The big limitation of this study was that the authors did not examine the gut microbiota to confirm the mechanism of action suggested. Further these results remain controversial as similar studies did not find significant changes in the values of TNF- $\alpha$  after treatment with different Probiotics<sup>64,65</sup> and different synbiotics.<sup>67,70</sup> respectively. A big difference in different variables seen in these studies, that included the intervention period, probiotic doses along with bacterial strains used along with the study

subjects. Thus positive effects were produced by some probiotics, by improving liver function and decreasing SIBO. Regarding some synbiotics, a reduction in liver fat and TNF- $\alpha$  production, caused prevention of NAFLD. Further Porras et al.,<sup>71</sup> reviewed how modulating intestinal microbiota in obesity related NAFLD by use of Probiotics, Probiotics, fecal microbiota transplantation works,<sup>71</sup> (Figure 1) (Figure 2). Despite these beneficial effects most of studies were of poor quality, from which conclusions can't be drawn. However studies where there was a limited risk of bias, sample size was mostly small, with significant differences in the type and dosage of the prescribed probiotic, treatment duration and feeding type can be shown. The natural modification of the gut microbiota composition during the 1<sup>st</sup> periods of life and the role of external factors like diet and antibiotic consumption in inducing dysbiosis are poorly or not taken into account. In addition the results are usually conflicting. All these factors answer why pooling data to meta-analysis is difficult and hence results of various meta-analyses vary. Park and Bae carried out a meta-analysis of the studies based on use of Probiotics for weight loss that got published till Dec 28 2014, excluding those enrolling pregnant women and infants. They selected 368 articles to begin with. But only 9 were randomized controlled trials (RCT), of which only 4 got included in the meta-analysis, since only in these studies means and SD regarding body weight was provided. Roughly 100 subjects got treated with probiotics, while 100 got placebo. Changes in body weight, BMI and if possible VFM were studied. No significant differences between groups were observed. Similarly a difference in VFM was not much. Hence the authors concluded that probiotics were ineffective in controlling weight changes.<sup>72</sup> In another meta-analysis carried out by Borgeraas et al similar conclusions got drawn.<sup>73</sup> In contrast markedly different results were reported in another meta-analysis done recently where studies until 2017 on the treatment of overweight and obese adults were considered [103]. Of 8009 studies identified, 21 RCT got analyzed.



**Figure 1** Courtesy ref 71-Mechanisms linking dysbiosis to NAFLD development. Dysbiotic gut microbiota is related to increased intestinal permeability and delivery of harmful substances (LPS, EtOH) to the liver, inducing inflammatory pathways mediated by PRRs. Inhibition of FIAF by IM promotes expression of lipogenic enzymes. Microbiota can modify bile acid pool in a mechanism associated to insulin resistance and lipogenesis enhancement. Choline metabolism is also affected by imbalanced microbiota, reducing lipid exportation through VLDL. ACC, acetyl-coA carboxylase; ChREBP, carbohydrate-responsive element-binding protein; EtOH, ethanol; FAS, fatty acid synthase; FIAF, fasting-induced adipocyte factor; IL, interleukin; IR, insulin resistance; LPS, lipopolysaccharide; NF- $\kappa$ B, nuclear factor kappa B; NLRP3, NOD-like receptor family, pyrin domain containing 3; SCFAs, short chain fatty acids; SREBP1-c, sterol regulatory element-binding protein 1c; TLR4, toll-like receptor 4; TNF- $\alpha$ , tumor necrosis factor  $\alpha$ ; VLDL, very low-density lipoprotein.



**Figure 2** NAFLD Courtesy ref no-71-Metabolic effects frequently associated to different microbiome-based therapies for obesity-associated NALFD and relevant changes reported in microbiota composition. SCFAs, short chain fatty acids. The figure was made with use of Smart Servier Medical Art, licensed under a Creative Common Attribution 3.0 Un ported License.

Probiotics use was associated with a significant decrease in all parameters like weight; VFM. But data on probiotic usage was conflicting. Low dose was associated with a lower BMI decrease although VFM decrease was greater. Further a longer period of probiotics use even with low dose =>significant decrease of both weight and BMI. Thus Wang et al.,<sup>74</sup> concluded that use of dietary agents for modulating gut microbiota was an essential tool for treatment of obesity.<sup>74</sup> Yet different conclusions got drawn by Drer et al in another meta-analysis, where RCTs and crossover trials were taken into account and results were stratified by age.<sup>75</sup> Studies involving pregnant women with term babies, neonates and individuals having GIT problems which might mask the effect of gut microbiota modulation were excluded. Starting from >1000 articles, 35 studies (14 in adults, 7 in children and 14 in infants) were considered to have a relatively low risk of bias and were analyzed. Use of different Lactobacillus strains ( $2.7 \times 10^{10}$  cfu/day of Probiotics usage for 2-3mths was associated with significant weight loss .The amount of weight loss differed from study to study, although these variations were not considered to be dependent on type of probiotic used, intervention duration or characteristics of the baseline population. In children a significant increase in weight of the subjects receiving probiotics was seen as compared to control. Similar results were seen in infants receiving a probiotic enriched formula from the age of 3weeks to 10mths .Further data showing a potential positive effect on weight gain from probiotic usage has been published recently. Jones et al conducted a double blind, RCT, which was placebo controlled in 19 obese adolescents, where 3 packets/day of a mixture of Lactobacillus species (*L. acidophilus* BA05, *L. plantarium* BP06, *L. paracasei* BP07, *L. delbriecki* sub sp bulgarius BD08), Bifid bacterium species (*B. breve* BB02, *B. longum* BL03, *B. infantis* BL04) and streptococcus thermopiles BT01 for 16weeks .In contrast to placebo adolescents who got Probiotics had significantly increased adiposity with no significant effects on gut microbiota, gut appetite regulating hormones, liver fat and fibrosis or dietary intake.<sup>76</sup>

## Conclusion

The human gut is a place for trillions of bacteria that are collectively called gut microbiota. This universe ecosystem has evolved simultaneously with us and has a direct connection in the physiological processes, which might affect many organ systems like CVS, neural, immune and metabolic .In the past few decades research has made our understanding in the role of microbiota in energy homeostasis. There is evidence that bacterial strains are in a special equilibrium with obesity, but the question arises which microbial community is causally linked to obesity is still not clear. Although both in animal and humans it has been tried to correct gut dysbiosis by targeting gut microbiota, but the work is still in early stages and limited human data to make meaningful conclusions beyond simple association ,that has the risk of misinterpretations, or giving excess value to expected results when translating animal protocol to human trials. Future work is needed to understand how changes in the gut microbiota =>obesity or how obesity has an impact on changes in micro biome composition. The double interactions between the host and flora that includes genetic material exchange may hold the answer to meaningful clinical translation. More understanding of this complex crosstalk will help in the development of specially tailored along with targeted implementation of probiotic therapies. Further most of the earlier studies had been done in tightly controlled animal models that limit their potential application in humans subjects and whatever studies done in humans show limitations and contradictory results and need to be better stratified based on specific markers which consider lifestyle, age, genetics and other environmental influences on microbial composition. Understanding the metagenomic relationship between changing microbiota and probiotic species under different diets/nutritional status are needed. Most of research in this dynamic field has been done using Lactobacillus and, Bifid bacterium strains; hence there is necessity for finding new bacterial candidates along with their potential mechanistic effects on obesity. Till now clinical

cohorts used have had small sample size and only focused on short term physical parameters, or inflammatory markers, which make long term studies highly important in future, work. Also randomized placebo controlled trials might help in developing guidelines for the use of Probiotics therapies in obesity and formulate nutritional recommendations besides addressing safety concerns regarding functional foods which contain Probiotics like fermented dairy products. Queries about specific bacterial strains's effect on bacterial composition, duration of therapy and appropriate doses still need an answer. But despite these pitfalls, probiotic therapy represents an exciting new avenue for medical treatment of obesity and associated metabolic dysfunctions, that we have been looking for.

## Acknowledgments

None.

## Conflicts of interest

The authors declared there is no conflicts of interest.

## References

1. World Health Organization Overweight and Obesity.
2. Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. *Prog Cardiovasc Dis.* 2014;56(4):369–381.
3. Chu DT, Minh Nguyet NT, Dinh TC, et al. An update on physical health and economic consequences of overweight and obesity. *Diabetes Metab Syndr.* 2018;12(6):1095–1100.
4. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Current Management of obesity in an infertile female–Recent Advances and Future Prospective Drugs. *Life science Global.* 2013;3(3):1–13.
5. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. An Update on Aetiopathogenesis and Management of Obesity. *Obesity and Control Therapies: Open Access.* 2016;3(1):1–17.
6. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Further Update on The Management of Obesity with emphasis on genetic perspective. *BAOJ Obes Weigt Manage.* 2017;3(1):010.
7. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Existing and prospective pathways for intervention in treatment of obesity in a novel way—a review. *MOJ Drug Des Develop Ther.* 2018;2(3):95–105.
8. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Can Thylakoids Replace Bariatric Surgery for Long Term Maintenance of Weight Loss in Obesity Giving A More Physiological Approach? *Obes Control Ther.* 2018;5(1):1–10.
9. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. An Update on Bariatric Surgery with Long Term Efficacy and Its Utilization for Medical Therapy Development from the Different Mechanism of Action and Other Short Comes to Be Outcome. *BAOJ Surgery.* 2018;4(2):038.
10. Abu–Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* 2010;7(12):691–701.
11. Heno–Mejia J, Elinav E, Jin C, Hao L, et al. Inflammasome–mediated dysbiosis regulates progression of NAFLD and obesity. *Nature.* 2012;482:179–185.
12. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia–induced inflammation in high–fat diet induced obesity and diabetes in mice. *Diabetes.* 2008;57(6):1470–1481.
13. Sircana A, Framarin L, Leone N, et al. Altered gut microbiota in type 2 diabetes: Just a coincidence? *Curr Diab Rep.* 2018;18(10):98.
14. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia–induced inflammation in high–fat diet induced obesity and diabetes in mice. *Diabetes.* 2008;57:1470–1481.
15. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature.* 2008;455(7216):1109–1113.
16. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity–associated gut microbiome with increased capacity for energy harvest. *Nature.* 2006;444(7122):1027–1031.
17. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *Nature.* 2009;457:480–484.
18. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Weight loss Associated with high protein Intake in Obesity:Interactions of Gut Microbiota in Protein Sources influencing this positive effect. *Acta Scientific Nutritional Health.* 2018;2(7):80–89.
19. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Current Advances in Pathogenesis in Obesity: Impact of Hypothalamic Glioses. *J Obes Weight Loss.* 2018;3:008:1–11.
20. Food and Agricultural Organization (FAO). Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the evaluation of Probiotics in Food. Canada. 2002.
21. Hill C, Guarner F, Reid G, et al. Expert Consensus Document:The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of term probiotic. *Nat Rev Gastroenterol Hepatol.* 2014;11(8):506–514.
22. Plaza–Diaz I, Gomez–Llorente C, Abadia–Molina F, et al. Effects of Lactobacillus paracasei CNCM I–4034, Bifidobacterium breve CNCM I–4035, and Lactobacillus thamnosus CNCM I–4036 on hepatic steatosis in Zucker rats. *PLOS ONE.* 2014;9:e98401.
23. World Health Organization and Food and Agricultural Organization in the United Nations. Health and Nutritional Properties in the Food including Powder milk with Live Lactic Acid Bacteria. FAO Nutrition Paper; FAO, Cordoba, Argentina. 2001;85:1–33.
24. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escheria Coli Nissle 1917is as effective as with standard mesalazine. *Gut.* 2004;53(11):1617–1623.
25. Bermudez–Brilo M, Plaza–Diaz I, Munoz–Quezada S, et al. Probiotic mechanisms of action. *Ann Nutr Metab.* 2012;61(12):160–174.
26. Fontana I, Bermudez–Brilo M, Plaza–Diaz I, et al. Gil A. Sources, isolation, characterisation and evaluation of probiotics. *Br J Nutr.* 2013;2:S35–S50.
27. Pineiro M, Asp NG, Reid G, et al. FAO Technical meeting on probiotics. *J Clin Gastroenterol.* 2008;42:S156–S159.
28. Upadhyay N, Moudga LV. Probiotics: A Review. *J Clin Outcomes Manag.* 2012;19:76–81.
29. Plaza–Diaz I, Fernandez–Caballero JA, Chueca N, et al. Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains. *Nutrients.* 2015;7(6):3999–4015.
30. Kim SW, Suda W, Kim S, et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high throughput pyrosequencing. *DNA Res.* 2013;20(3):241–253.
31. Ferraro C, Taverniti V, Milani C, et al. Modulation of fecal Clostridial bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DC, varies among healthy adults. *J Nutr.* 2014;144(11):1787–1796.
32. Yoo JY, Kim SS. Probiotics and Prebiotics. Present status and future perspectives on metabolic disorders. *Nutrients.* 2016;18(8):173.

33. Laursen N, Vogensen FK, Gobel RJ, et al. Effect of Lactobacillus salivarius Ls33 on faecal microbiota in obese adolescents. *Clin Nutr*. 2013;32(6):935–940.
34. Gobel RJ, Laursen N, Jacobsen M, et al. Probiotics to adolescents with obesity. Effect on inflammation and metabolic syndrome. *J Paediatr Gastroenterol Nutr*. 2012;55(6):673–678.
35. Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal obesity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. *Eur J Clin Nutr*. 2010;64(6):636–643.
36. Kadooka Y, Sato M, Ogawa A, et al. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal obesity in adults in a randomized controlled trial. *Br J Nutr*. 2013;110(9):1696–1703.
37. Sharafedinov KK, Plotnikova OA, Alexeeva RI, et al. Hypocalorie diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients—A randomized double blind, placebo controlled pilot study. *Nutr J*. 2013;12:138.
38. Zarrati M, Salehi E, Nourijelyani K, et al. Effect of probiotic yogurt on fat distribution and gene expression of proinflammatory factors in peripheral blood mononuclear cells in overweight and obese people with or without weight loss diet. *J Am Coll Nutr*. 2014;33(6):417–425.
39. Zarrati M, Shidfar F, Nourijelyani K, et al. Lactobacillus acidophilus La5, Bifidobacterium BB12 and Lactobacillus casei DN001 modulate gene expression of subset specific transcription factors and cytokines in peripheral blood mononuclear cells of obese and overweight people. *Biofactors*. 2013;39(6):633–643.
40. Zarrati M, Salehi E, Mofid V, et al. Relationships between a probiotic consumption and IL10 and IL17 secreted by PBMC in overweight and obese people. *Iran J Allergy Asthma Immunol*. 2013;12(4):404–406.
41. Agerholm-Larsen L, Raben A, Haulrik N, Hansen AS, et al. Effects of 8 weeks intake of probiotic milk products on risks of cardiovascular diseases. *Eur J Clin Nutr*. 2000;54(4):288–297.
42. Rajkumar N, Mahmoud N, Kumar M, Varikuti SR, et al. Effects of probiotic (VSL#3) and -3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults. A randomized controlled trial. *Mediat Inflamm*. 2014;34:8959.
43. Brahe LK, Le Chatalier E, Pifti E, et al. Dietary modulation of the gut microbiota—A randomized controlled trial in obese postmenopausal women. *Br J Nutr*. 2015;114(3):406–417.
44. Ivey KL, Hodgson JM, Kerr DA, et al. The effect of probiotic bacteria on glycaemic control in overweight men and women: A randomized controlled trial. *Eur J Clin Nutr*. 2014;68(4):447–452.
45. Ivey KL, Hodgson JM, Kerr DA, et al. The effect of yogurt and its probiotics on blood pressure and serum lipid profile: A randomized controlled trial. *Nutr Metab Cardiovasc Dis*. 2015;25(1):46–51.
46. Sanchez M, Darimont C, Drapeau V, et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. *Br J Nutr*. 2014;111(8):1507–1519.
47. Safavi M, Tarajian S, Kelishadi R, et al. The effects of synbiotic supplementation on some cardiometabolic risk factors in overweight and obese children: A randomized triple masked controlled trial. *Int J Food Sci Nutr*. 2013;64(6):687–693.
48. Ipar N, Avdogdu SD, Yildirim GK, et al. Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children. *Benef Microbes*. 2015;6(6):775–781.
49. Leber B, Tripolt NJ, Blattl D, et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome. An open label, randomized pilot study. *Eur J Clin Nutr*. 2012;66(10):1110–1115.
50. Barreto FM, Colado-Simao AN, Morimato HK, et al. Helena-da Silva Mighoranza L. Beneficial effect of Lactobacillus planetarium on glycaemia and homocysteine levels in postmenopausal women with metabolic syndrome. *Nutrition*. 2014;30:39–942.
51. Renorio-Jimenez C, Martinez-Rmirez MJ, Tercero-Lozano M, et al. Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: A randomized clinical trial (PROSIR). *BMC Complement Altern Med*. 2018;18(1):306.
52. Eslamparasi T, Zamani F, Hekmatdoost A, et al. With metabolic syndrome. A randomized, double blind, placebo-controlled pilot study. *Br J Nutr*. 2014;112(3):438–445.
53. Hariri M, Salehi R, Feizi A, et al. A randomized, double blind, placebo-controlled clinical trial on probiotic soy milk and soymilk: Effects on epigenetics and oxidative stress in patients with type II diabetes. *Genes Nutr*. 2015;10(6):52.
54. Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, et al. Clinical application of probiotics in type 2 diabetic patients: A randomized, double blind, placebo-controlled study. *Clin Nutr*. 2015.
55. Mohammadshahi M, Veissi M, Haidari F, et al. Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial. *J Res Med Sci*. 2014;19(6):531–536.
56. Ejahed AC, Mohtadi Nia J, Homayouni Rad A, et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutrition*. 2012;28(5):539–543.
57. Ejahed AC, Mohtadi Nia J, Homayouni Rad A, et al. Effects of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium brevis on lipid profile in individuals with type 2 diabetes mellitus. *J Dairy Sci*. 2011;94(7):3288–3294.
58. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. *Br J Nutr*. 2010;104(12):1831–1838.
59. Razmpoosh E, Javad A, Ejtahed HS, et al. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial. *Diabetes Metab Syndr*. 2019;13(1):175–182.
60. Asemi Z, Zohreh Z, Shakeri H, Sima-Sadat Sabihi SS, et al. Effects of multispecies probiotic supplements on metabolic profile, hs-CRP and oxidative stress in patients with type 2 diabetes mellitus. *Ann Nutr Metab*. 2013;63(1-2):1–9.
61. Tajadadi-Ebrahimi M, Bahmani F, Shakeri H, et al. Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C reactive protein among diabetic patients. A double blind, randomized controlled clinical trial. *Ann Nutr Metab*. 2014;65(1):34–41.
62. Shakeri H, Hadaegh H, Abedi F, et al. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type 2 diabetes mellitus. *Lipids*. 2014;49(7):695–701.
63. Moroti C, Souza-Magri LF, Rezende-Costa M, et al. Effects of the consumption of new symbiotic shake on glycaemia and cholesterol levels in elderly people with type 2 diabetes mellitus. *Lipids Health Dis*. 2012;11:29.
64. Aller R, De Luis DA, Laola O, et al. Effect of a probiotic on liver aminotransferases in non fatty liver disease patients: A double blind, randomized clinical trial. *Eur Rev Med Pharmacol Sci*. 2011;15(19):1090–1095.
65. Vajro R, Mandato C, Licenziati MR, et al. Effect of Lactobacillus rhamnosus strain GG in paediatric obesity-related liver disease. *J Gastroenterol Nutr*. 2011;52(6):740–743.

66. Nabavi S, Rafrat M, Somi HH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with non alcoholic fatty liver disease. *J Dairy Sci.* 2014;97(12):7386–7393.
67. Alisi A, Bedogni C, Baviera G, et al. Randomized clinical trial: The beneficial effect of VSL#3 in obese children with non alcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2014;39(11):1276–1285.
68. Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in non alcoholic fatty liver disease. A randomized double blind, placebo-controlled pilot study. *Am J Clin Nutr.* 2014;99(3):535–542.
69. Lirussi E, Mastropasqua E, Orando S, et al. Probiotics for non alcoholic fatty liver disease and/or steatohepatitis. *Cochrane Database Syst Rev.* 2007;24(1):CD05165.
70. Wong VW, Won GL, Chim AM, et al. Treatment of non alcoholic steatohepatitis with probiotics. A proof of concept study. *Ann Hepatol.* 2013;12(2):256–262.
71. Porras D, Nisini E, Martinez-Perez S, Gonzalez-Gallego J, et al. Intestinal Microbiota modulation in Obesity Related non alcoholic fatty liver Disease. *Front Physiol.* 2018;9:1813.
72. Park S, Bae JH. Probiotics for weight loss: A systematic review and Effects of meta-analysis. *Nutr Res.* 2015;35(7):566–575.
73. Borgeraas H, Johnson LK, Skattebu J, et al. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: A systematic review and meta-analysis of randomized controlled trials. *Obes. Rev.* 2018;19(2):219–232.
74. John GK, Wang L, Nanavati J, et al. Dietary alteration of the gut microbiome and its impact on weight and fat mass: A systematic review and meta-analysis. *Genes.* 2018;9(3):167.
75. Dror T, Dickstein Y, Dubourg G, et al. Microbiota manipulation for weight change. *Microb Pathog.* 2017;106:146–161.
76. Jones RB, Alderete TL, Martin AA, et al. Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: A 16-week, randomized, placebo-controlled trial. *Pediatr Obes.* 2017;13:705–714.